Advertisement
BNTX vs MRNA
Which Stock Would AI Choose? BioNTech SE (BNTX) vs. Moderna, Inc. (MRNA) Stock Comparison
Key Takeaways
- MRNA has delivered stronger year-to-date performance at 53.85%, outpacing BNTX's 2.37% amid biotech sector volatility.
- BNTX maintains superior cash reserves of $13.74 billion compared to MRNA's $5.21 billion, supporting extended R&D runway.
- Recent Phase 2 data for BNTX's antibody-drug conjugate (ADC) in endometrial cancer drove stock surges in recent weeks.
- MRNA reported Q1 2026 revenue of $389 million, up 260% year-over-year, though litigation costs widened losses.
- Both stocks reflect post-COVID revenue pressures but advance oncology pipelines as key growth drivers.
- BNTX market cap stands at $24.67 billion, larger than MRNA's $17.99 billion.
Introduction
BioNTech SE (BNTX) and Moderna, Inc. (MRNA) remain pivotal players in the mRNA biotechnology space, renowned for their COVID-19 vaccines developed in partnership and independently. As demand for pandemic-era products wanes, both companies pivot toward oncology and infectious disease pipelines. This stock comparison analyzes their recent market performance, financial health, and strategic shifts, aiding traders seeking short-term momentum and investors focused on long-term biotech innovation in the current environment.
BNTX Overview and Recent Performance
BioNTech SE (BNTX), a German biotechnology firm, specializes in mRNA-based immunotherapies, best known for co-developing the Comirnaty COVID-19 vaccine with Pfizer. The company is transitioning to a multi-product oncology leader, with a diversified pipeline targeting solid tumors and other cancers. In recent market activity, BNTX shares surged following positive Phase 2 data for trastuzumab pamirtecan, an antibody-drug conjugate (ADC), demonstrating efficacy in HER2-expressing recurrent endometrial cancer. This catalyzed gains of over 9% in a session, alongside analyst price target adjustments. Closing at $97.54 on May 1, 2026, with a market cap of $24.67 billion, sentiment has been buoyed by upcoming Q1 2026 earnings on May 5 and strategic oncology readouts expected throughout the year. Robust cash holdings of $13.74 billion underpin R&D amid declining vaccine revenues.
MRNA Overview and Recent Performance
Moderna, Inc. (MRNA), a U.S.-based pioneer in mRNA therapeutics, gained prominence with its Spikevax COVID-19 vaccine. The firm pursues vaccines for respiratory viruses and oncology applications. Recent weeks saw volatility post-Q1 2026 earnings, reporting $389 million in revenue—a 260% year-over-year increase driven by international COVID vaccine sales—yet a widened net loss from a $0.9 billion litigation charge. Shares dipped around 10% initially but showed resilience. Closing at $45.37 on May 1, 2026, with a $17.99 billion market cap, MRNA reaffirmed a 10% full-year revenue growth outlook, supported by pipeline progress and new approvals. Year-to-date gains of 53.85% reflect optimism despite cash at $5.21 billion and ongoing post-pandemic adjustments.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. Out of 351 total bots, 25 trending ones feature impressive stats, including annualized returns ranging from +23.53% to +163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70. These bots employ varied approaches like trend trading, swing trading, and multi-agent systems with technical and fundamental analysis, spanning timeframes from 1 day to 49 days. Ideal for current market conditions, they offer real-time signals tailored to stocks, ETFs, and sectors. Explore these high-performing options to enhance your trading edge.
Head-to-Head Comparison
Both BNTX and MRNA leverage mRNA platforms but diverge in focus: BNTX emphasizes oncology with multiple late-stage trials, while MRNA balances vaccines and cancer therapies. Growth drivers include BNTX's anticipated 2026 oncology data readouts versus MRNA's international vaccine expansions. Recent momentum favors MRNA with robust YTD gains, though BNTX shows steadier recent upticks on clinical wins. Risk factors encompass pipeline failures, regulatory hurdles, and COVID revenue declines, with BNTX's higher beta (1.59) signaling greater volatility than MRNA's (1.06). Market sentiment tilts toward BNTX for financial strength but MRNA for near-term revenue visibility.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BNTX, citing its superior cash position, consistent oncology catalysts like recent ADC data, and relative stability versus MRNA's litigation-impacted earnings. While MRNA offers stronger short-term momentum, BNTX's pipeline positioning suggests higher probability of sustained upside in the evolving biotech landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and MRNA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNTX’s FA Score shows that 2 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).
- BNTX’s FA Score: 2 green, 3 red.
- MRNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNTX’s TA Score shows that 3 TA indicator(s) are bullish while MRNA’s TA Score has 4 bullish TA indicator(s).
- BNTX’s TA Score: 3 bullish, 6 bearish.
- MRNA’s TA Score: 4 bullish, 5 bearish.
Price Growth
BNTX (@Biotechnology) experienced а -8.20% price change this week, while MRNA (@Biotechnology) price change was +0.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -7.98%, and the average quarterly price growth was -1.75%.
Reported Earning Dates
BNTX is expected to report earnings on Aug 04, 2026.
MRNA is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BNTX | MRNA | BNTX / MRNA | |
| Capitalization | 22.3B | 18.8B | 119% |
| EBITDA | -697.7M | -2.88B | 24% |
| Gain YTD | -7.479 | 60.868 | -12% |
| P/E Ratio | 161.76 | N/A | - |
| Revenue | 2.81B | 2.2B | 127% |
| Total Cash | 14.6B | 5.21B | 280% |
| Total Debt | 303M | 1.3B | 23% |
BNTX | MRNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 98 | |
PRICE GROWTH RATING 1..100 | 72 | 39 | |
P/E GROWTH RATING 1..100 | 1 | 2 | |
SEASONALITY SCORE 1..100 | 30 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTX's Valuation (2) in the null industry is significantly better than the same rating for MRNA (78) in the Biotechnology industry. This means that BNTX’s stock grew significantly faster than MRNA’s over the last 12 months.
BNTX's Profit vs Risk Rating (100) in the null industry is in the same range as MRNA (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
BNTX's SMR Rating (94) in the null industry is in the same range as MRNA (98) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for BNTX (72) in the null industry. This means that MRNA’s stock grew somewhat faster than BNTX’s over the last 12 months.
BNTX's P/E Growth Rating (1) in the null industry is in the same range as MRNA (2) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
| BNTX | MRNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 3 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| Advances ODDS (%) | 9 days ago 70% | 3 days ago 79% |
| Declines ODDS (%) | 4 days ago 81% | 5 days ago 87% |
| BollingerBands ODDS (%) | N/A | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 82% | N/A |
Advertisement
BNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To BNTX | 1D Price Change % | ||
|---|---|---|---|---|
| BNTX | 100% | -1.69% | ||
| MRNA - BNTX | 47% Loosely correlated | -8.04% | ||
| AXON - BNTX | 43% Loosely correlated | -5.28% | ||
| VERA - BNTX | 39% Loosely correlated | -3.33% | ||
| RZLT - BNTX | 37% Loosely correlated | -5.65% | ||
| KYMR - BNTX | 36% Loosely correlated | -0.64% | ||
More | ||||
MRNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with NVAX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then NVAX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | -8.04% | ||
| NVAX - MRNA | 53% Loosely correlated | -6.87% | ||
| BNTX - MRNA | 47% Loosely correlated | -1.69% | ||
| MRVI - MRNA | 45% Loosely correlated | +0.60% | ||
| CRBU - MRNA | 43% Loosely correlated | -7.02% | ||
| CRSP - MRNA | 42% Loosely correlated | -8.97% | ||
More | ||||